Actelion has posted its financial results for the first half of 2009. The company posts total net revenues of CHF855.2 million, an increase of 27% for the first six months of 2009, compared to same period of 2008. The company has also reported an operating profit of CHF242.9 million.
In the first half of 2009, the company reported a net profit of CHF 218.4 million, an increase of 83% from the previous year’s same period.
Jean-Paul Clozel, MD and CEO, Actelion, said: “I am very pleased with our performance in the first six months of 2009. We are making significant headway towards obtaining clinical data in the months ahead that might turn development compounds into tomorrow’s pharmaceutical options.
“I am especially pleased with the promising results of our PGI2 receptor agonist that allows for accelerated development as an oral agent stimulating the prostacyclin pathway. We have also entered a novel anti-infective into clinical development, thereby demonstrating our commitment to bringing our platform approach in research to fruition in multiple areas of high unmet medical demand,” he added.